Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
Status:
Completed
Trial end date:
2016-03-04
Target enrollment:
Participant gender:
Summary
This is a single center pilot study in which Laronidase will be given weekly for two years in
patients with Hurler syndrome, also known as mucopolysaccharide IH (MPS I, Hurler syndrome),
that have previously been treated with an allogeneic transplant.